*** TEST ***
Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
[thumbnail of Supplementary Information] Other (Supplementary Information)
8MB

Item Type:Article
Title:High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers
Creators Name:Del Moral-Sánchez, I., Russell, R.A., Schermer, E.E., Cottrell, C.A., Allen, J.D., Torrents de la Peña, A., LaBranche, C.., Kumar, S., Crispin, M., Ward, A.B., Montefiori, D.C., Sattentau, Q.J., Sliepen, K. and Sanders, R.W.
Abstract:Soluble HIV-1 envelope glycoprotein (Env) immunogens are a prime constituent of candidate vaccines designed to induce broadly neutralizing antibodies. Several lines of evidence suggest that enhancing Env immunogen thermostability can improve neutralizing antibody (NAb) responses. Here, we generated BG505 SOSIP.v9 trimers, which displayed virtually no reactivity with non-neutralizing antibodies and showed increased global and epitope thermostability, compared to previous BG505 SOSIP versions. Chemical crosslinking of BG505 SOSIP.v9 further increased the melting temperature to 91.3 °C, which is almost 25 °C higher than that of the prototype SOSIP.664 trimer. Next, we compared the immunogenicity of a palette of BG505-based SOSIP trimers with a gradient of thermostabilities in rabbits. We also included SOSIP.v9 proteins in which a strain-specific immunodominant epitope was masked by glycans to redirect the NAb response to other subdominant epitopes. We found that increased trimer thermostability correlated with increased potency and consistency of the autologous NAb response. Furthermore, glycan masking steered the NAb response to subdominant epitopes without decreasing the potency of the autologous NAb response. In summary, SOSIP.v9 trimers and their glycan masked versions represent an improved platform for HIV-1 Env based vaccination strategies.
Source:NPJ Vaccines
ISSN:2059-0105
Publisher:Springer Nature
Volume:7
Number:1
Page Range:27
Date:28 February 2022
Official Publication:https://doi.org/10.1038/s41541-022-00446-4
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library